H.C. Wainwright lowered the firm’s price target on Elicio Therapeutics to $10 from $11 and keeps a Buy rating on the shares. The analyst says the ELI-002 clinical data appears promising.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELTX:
- Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting
- Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates
- Elicio Therapeutics to sell 1.03M shares $5.81 in private placement financing
- Elicio Therapeutics Announces $6.0 Million Private Placement Financing
- Elicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting